High-grade glioma in elderly patients: Can the oncogeriatrician help?

Clinical Interventions in Aging

Volumn 8, Issue , 2013, Pages 1617-1624

  Tabouret, Emeline ^a   Tassy, Louis ^b   Chinot, Olivier ^a   Crétel, Elodie ^a   Retornaz, Frederique ^c   Rousseau, Frederique ^d  

^a TIMONE HOSPITAL   (France)

^b CENTRE LÉON BÉRARD   (France)

^c Departmental Gerontologic Centre   (France)

^d INSTITUT PAOLI CALMETTES   (France)

Author keywords

Brain tumor; Chemotherapy toxicity; Older cancer patient; Oncogeriatric charter

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; ANTICONVULSIVE AGENT; BEVACIZUMAB; CARMUSTINE; CORTICOSTEROID; FOTEMUSTINE; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ASTROCYTOMA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER PROGNOSIS; CLINICAL FEATURE; COMORBIDITY; DNA METHYLATION; DRUG TOLERANCE; EDEMA; EVENT FREE SURVIVAL; FUNCTIONAL STATUS; GERIATRIC ASSESSMENT; GERIATRIC PATIENT; GLIOBLASTOMA; GLIOMA; HIGH RISK POPULATION; HUMAN; HYPERTENSION; KARNOFSKY PERFORMANCE STATUS; MOLECULARLY TARGETED THERAPY; NEUROSURGERY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGERIATRICIAN; OSTEOPOROSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; POLYPHARMACY; PROMOTER REGION; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR EDEMA;

BRAIN TUMOR; CHEMOTHERAPY TOXICITY; OLDER CANCER PATIENT; ONCOGERIATRIC CHARTER;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; GLIOMA; HUMANS; PROGNOSIS;

EID: 84889585292     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S35941     Document Type: Review

References (62)

1. Greig NH, Ries LG, Yancik R, Rapoport SI. Increasing annual incidence of primary malignant brain tumors in the elderly. J Natl Cancer Inst. 1990;82:1621-1624.
2. Chakrabarti I, Cockburn M, Cozen W, Wang YP, Preston-Martin S. A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999. Cancer. 2005;104:2798-2806.
3. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704-710.
4. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114: 97-109.
5. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2012;31:337-343.
6. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2012;31:344-350.
7. Reifenberger G, Hentschel B, Felsberg J, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer. 2012;131:1342-1350.
8. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2009;13: 707-715.
9. Wiestler B, Claus R, Hartlieb SA, et al. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro Oncol. 2013;15:1017-1026.
10. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061-1068.
11. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009;72:1217-1222.
12. Sana J, Hajduch M, Michalek J, Vyzula R, Slaby O. MicroRNAs and glioblastoma: roles in core signalling pathways and potential clinical implications. J Cell Mol Med. 2011;15:1636-1644.
13. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet. 2012;379:1984-1996.
14. Deorah S, Lynch CF, Sibenaller ZA, Ryken TC. Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus. 2006;20:E1.
15. Lowry JK, Snyder JJ, Lowry PW. Brain tumors in the elderly: recent trends in a Minnesota cohort study. Arch Neurol. 1998;55:922-928.
16. Burkhardt K, Heuberger F, Delavelle J. Pilocytic astrocytoma in the elderly. Clin Neuropathol. 2007;26:306-310.
17. Benson VS, Pirie K, Schüz J, Reeves GK, Beral V, Green J. Mobile phone use and risk of brain neoplasms and other cancers: prospective study. Int J Epidemiol. 2013;42:792-802
18. Iwamoto FM, Cooper AR, Reiner AS, Nayak L, Abrey LE. Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997-2007). Cancer. 2009;115:3758-3766.
19. Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9:906-920.
20. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963-1972.
21. Iwamoto FM, Reiner AS, Nayak L, Panageas KS, Elkin EB, Abrey LE. Prognosis and patterns of care in elderly patients with glioma. Cancer. 2009;115:5534-5540.
22. Lutterbach J, Bartelt S, Momm F, Becker G, Frommhold H, Ostertag C. Is older age associated with a worse prognosis due to different patterns of care? A long-term study of 1346 patients with glioblastomas or brain metastases. Cancer. 2005;103:1234-1244.
23. Villà S, Viñolas N, Verger E, et al. Efficacy of radiotherapy for malignant gliomas in elderly patients. Int J Radiat Oncol Biol Phys. 1998;42: 977-980.
24. Tanaka S, Meyer FB, Buckner JC, Uhm JH, Yan ES, Parney IF. Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients. J Neurosurg. 2013;118:786-798.
25. Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64:628-634.
26. Fiorentino A, Caivano R, Chiumento C, et al. Comorbidity assessment and adjuvant radiochemotherapy in elderly affected by glioblastoma. Med Oncol. 2012;29:3467-3471.
27. Mohan DS, Suh JH, Phan JL, Kupelian PA, Cohen BH, Barnett GH. Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Int J Radiat Oncol Biol Phys. 1998;42: 981-987.
28. Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer. 2003;97:2262-2266.
29. Scott JG, Bauchet L, Fraum TJ, et al. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer. 2012;118:5595-5600.
30. Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys. 1993;26:239-244.
31. Martinez R, Janka M, Soldner F, Behr R. Gross-total resection of malignant gliomas in elderly patients: implications in survival. Zentralbl Neurochir. 2007;68:176-181.
32. Vuorinen V, Hinkka S, Färkkilä M, Jääskeläinen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien). 2003;145:5-10.
33. Menei P, Metellus P, Parot-Schinkel E, et al. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol. 2010;17:1740-1746.
34. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5: 79-88.
35. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356:1527-1535.
36. Donato V, Monaco A, Rollo A, et al. Elderly and poor prognosis patients with high grade glioma: hypofractionated radiotherapy. Clin Ter. 2007;158:227-230.
37. Hoegler DB, Davey P. A prospective study of short course radiotherapy in elderly patients with malignant glioma. J Neurooncol. 1997;33: 201-204.
38. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22:1583-1588.
39. Chinot OL, Barrie M, Frauger E, et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer. 2004;100:2208-2214.
40. Gállego Pérez-Larraya J, Ducray F, Chinot O, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol. 2011;29: 3050-3055.
41. Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13:916-926.
42. Brandes AA, Vastola F, Basso U, et al. A prospective study on glioblastoma in the elderly. Cancer. 2003;97:657-662.
43. Santoni M, Scoccianti S, Lolli I, et al. Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. J Neurooncol. 2013;113:397-401.
44. Reithmeier T, Graf E, Piroth T, Trippel M, Pinsker MO, Nikkhah G. BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. BMC Cancer. 2010;10:30.
45. Grant R, Liang BC, Page MA, Crane DL, Greenberg HS, Junck L. Age influences chemotherapy response in astrocytomas. Neurology. 1995;45: 929-933.
46. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
47. Fiorentino A, Balducci M, De Bonis P, et al. Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials? Am J Clin Oncol. Epub February 5, 2013.
48. Minniti G, Scaringi C, Baldoni A, et al. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. Int J Radiat Oncol Biol Phys. 2013;86:285-291.
49. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740-745.
50. Tabouret E, Barrie M, Thiebaut A, et al. Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen. J Neurooncol. 2013;114:191-198.
51. Ahn GO, Brown JM. Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature. Angiogenesis. 2009;12:159-164.
52. Thomas TP. The complications of systemic corticosteroid therapy in the elderly. A retrospective study. Gerontology. 1984;30:60-65.
53. Kerkhof M, Dielemans JC, van Breemen MS, et al. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol. 2013;15:961-967.
54. Karnofsky DA. Chemotherapy of neoplastic disease; agents of clinical value. N Engl J Med. 1948;239:299-305.
55. Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8:810-818.
56. Audisio RA, Gennari R, Sunouchi K, et al. Preoperative assessment of cancer in elderly patients: a pilot study. Support Cancer Ther. 2003;1: 55-60.
57. Ramesh HS, Boase T, Audisio RA. Risk assessment for cancer surgery in elderly patients. Clin Interv Aging. 2006;1:221-227.
58. Cecile M, Seux V, Pauly V, et al. [Adverse drug events in hospitalized elderly patients in a geriatric medicine unit: study of prevalence and risk factors]. Rev Med Interne. 2009;30:393-400. French.
59. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352: 997-1003.
60. Minniti G, Lanzetta G, Scaringi C, et al. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2012;83: 93-99.
61. Minniti G, De Sanctis V, Muni R, et al. Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol. 2009;91:95-100.
62. Minniti G, De Sanctis V, Muni R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol. 2008;88:97-103.